Tag:

Bayer

Latest Headlines

Latest Headlines

Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts

Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas.

Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts

In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the company's second quarter results, Bayer is well on its way to making good on that goal.

Top 10 animal health companies of 2013

It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound...

Bayer's Nexavar misses another study endpoint, this time for breast cancer

Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication. 

As FDA regulations tighten, report says antimicrobial market headed for a crash

As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market.

UPDATED: Merck's Bravecto, Bayer's Quellin chewables approved for dogs

Bayer HealthCare has scored approval for the first chewable drug approved by the agency for treating osteoarthritis in dogs, a disease that accounts for pain in about 20% of canines older than one year.

Bayer likes all the brands it got from Merck, Coppertone and Dr. Scholl's included

Should Bayer sell some of the consumer brands it's buying from Merck in a $14 billion deal? Analysts say a few of them--Coppertone sun products, for instance--don't quite fit with Bayer's product lineup. Buyers appear to be knocking. But Bayer says it will keep those brands, thank you very much.

Japan OKs Bayer's Nexavar for thyroid cancer

Building on approvals in the U.S. and EU, Bayer Healthcare said Japan has approved  Nexavar  to treat patients with unresectable differentiated thyroid carcinoma.

Sources: Bayer, J&J's Xarelto faces first U.S. lawsuits

The inevitable has happened for Bayer's fast-selling anticoagulant blockbuster, Xarelto. Someone in the U.S. has filed a lawsuit over its safety concerns. In fact, a number of lawsuits have been filed, according to reports in a German newspaper.

Bayer drafts Otsuka exec to lead pharma biz to big growth

Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.